Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2018 | Predictors for TFR in CML: response duration, secondary treatment & frontline TKI choice

Timothy Hughes • 12 Sep 2018

SOHO 2018

Chronic Myeloid Leukemia Leukemia Imatinib

ENESTFreedom ENESTop EURO-SKI

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Timothy Hughes, MD, FRACP, FRCPA, of the Royal Adelaide Hospital, Adelaide, Australia, discusses predictors of treatment-free remission (TFR) in chronic myeloid leukemia (CML). Prof. Hughes highlights what the EURO-SKI trial (NCT01596114) demonstrated about the importance of the duration of a deep molecular response, and what ENESTop (NCT01698905) and other trials have shown about the impact of second-line treatment. He also explores what the ENESTFreedom study (NCT01784068) indicates about starting frontline treatment with a second generation TKI.

Managing drug resistance in CP-CML with ponatinib and asciminib

Timothy Hughes • 9 Dec 2023

The ALLG CML13 ASCEND-CML study: high major molecular responses with asciminib treatment for CP-CML

Timothy Hughes • 9 Dec 2023

The efficacy of nilotinib treatment approaches in frontline CML

Timothy Hughes • 12 Jun 2022

Clinical trial updates in CML

Timothy Hughes • 12 Jun 2022

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024